Geneva will not market generic captopril until February under consent agreement reached Nov. 20.
Executive Summary
GENEVA GENERIC CAPTOPRIL WILL NOT BE DISTRIBUTED UNTIL FEBRUARY under a consent agreement reached Nov. 20, CibaGeneva said. The company will hold off marketing a generic version of Bristol-Myers Squibb's ACE inhibitor Capoten until Bristol's GATT-extended patent expires Feb. 13, unless Congress amends the Waxman/Hatch Act to allow companies to market generics in the delta period between the original and the General Agreement on Tariffs & Trade expiration dates.